Rapt therapeutics, inc. (RAPT)
Income statement / TTM
Mar'20Sep'19Mar'19Sep'18
Revenue

0

-

-

-

Operating expenses:
Research and development

0

0

0

0

General and administrative

0

0

0

0

Total operating expenses

0

0

0

0

Loss from operations

0

0

0

0

Other income
Other income, net

0

0

0

0

Net loss before taxes

0

-

0

-

Provision for income taxes

0

-

0

-

Net loss

0

0

0

0

Other comprehensive loss:
Foreign currency translation adjustment

0

-

-

-

Unrealized loss on marketable securities

0

-

-

-

Other comprehensive income/(loss)

-

0

-

0

Total comprehensive loss

0

0

0

0

Net loss per share, basic and diluted

-0.56

-12.41

-13.28

-15.90

Weighted average number of shares used in computing net loss per share, basic and diluted

23,266,063

803,229

691,834

646,800